Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab +/- Docetaxel in Advanced NSCLC
NCT04023617Phase 2Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jul 2019
- Primary completion
- Jun 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Peking University Cancer Hospital & Institute. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04023617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04023617.